Serotonin 5-HT1A Receptors as Targets for Agents to Treat Psychiatric Disorders: Rationale and Current Status of Research

@article{Celada2013Serotonin5R,
  title={Serotonin 5-HT1A Receptors as Targets for Agents to Treat Psychiatric Disorders: Rationale and Current Status of Research},
  author={Pau Celada and Anal{\'i}a Bortolozzi and Francesc Casa{\~n}as Artigas},
  journal={CNS Drugs},
  year={2013},
  volume={27},
  pages={703-716}
}
Psychiatric disorders represent a large economic burden in modern societies. However, pharmacological treatments are still far from optimal. Drugs used in the treatment of major depressive disorder (MDD) and anxiety disorders (selective serotonin [5-HT] reuptake inhibitors [SSRIs] and serotonin-noradrenaline reuptake inhibitors [SNRIs]) are pharmacological refinements of first-generation tricyclic drugs, discovered by serendipity, and show low efficacy and slowness of onset. Moreover… 

Functional Selectivity and Antidepressant Activity of Serotonin 1A Receptor Ligands

Identifying brain specific molecular targets for 5-HT1A receptor ligands may result in a better targeting, raising a hope for more effective medicines for various pathologies.

The serotonergic system in the neurobiology of depression: Relevance for novel antidepressants

The novel antidepressants vortioxetine, vilazodone and milnacipran/levomilnacIPran are featured with regard to their serotonin receptor targets which may account for their specific effects on certain symptoms of depression as well as a characteristic side-effect profile.

Psychopharmacology of combined activation of the serotonin1A and &sgr;1 receptors

Revealing vilazodone's binding mechanism underlying its partial agonism to the 5-HT1A receptor in the treatment of major depressive disorder.

This newly identified binding mechanism underlying vilazodone's partial agonism to the 5-HT1A receptor will provide valuable information for medicinal chemists working in the field of rational design of novel SPARIs for MDD treatment.

A Neurobiological Hypothesis of Treatment-Resistant Depression – Mechanisms for Selective Serotonin Reuptake Inhibitor Non-Efficacy

It is proposed that TRD may not represent a simple serotonin deficit state but rather an excess of midbrain peri-raphe serotonin and subsequent deficit at key fronto-limbic projection sites, with ultimate compromise in serotonin-mediated neuroplasticity.

Chronic Treatment with the 5-HT1A Receptor Partial Agonist Tandospirone Increases Hippocampal Neurogenesis

The results strongly suggest that 5-HT1A receptor partial agonists would be useful and beneficial in the treatment of depressive and anxiety disorders through increased hippocampal neurogenesis.
...

References

SHOWING 1-10 OF 213 REFERENCES

Serotonin receptors involved in antidepressant effects.

  • F. Artigas
  • Biology, Psychology
    Pharmacology & therapeutics
  • 2013

5-HT1A receptor function in major depressive disorder

The role of serotonin receptor subtypes in treating depression: a review of animal studies

The involvement of 5- HT receptors in the antidepressant-like effects of SSRIs is complex and involves the orchestration of stimulation and blockade at different 5-HT receptor subtypes.

The 5-HT1A receptor in schizophrenia: a promising target for novel atypical neuroleptics?

There is now a sufficient rationale to examine thoroughly the role of the 5-HT1A receptor in schizophrenia and antipsychotic drug treatment, and the anticataleptic activity of 5- HT1A agonist augmentation of neuroleptics in the treatment of schizophrenia.

Therapeutic Role of 5‐HT1A Receptors in The Treatment of Schizophrenia and Parkinson's Disease

  • Y. Ohno
  • Psychology, Medicine
    CNS neuroscience & therapeutics
  • 2011
Evidence that 5‐HT1A receptors seem to be a promising target for alleviating antipsychotic‐induced extrapyramidal side effects (EPS) and cognitive/affective disorders in schizophrenia and Parkinson's disease should encourage discovery of new 5‐ HT1A ligands, which can resolve the unmet clinical needs in the current therapy.

Is there a role for 5-HT1A agonists in the treatment of depression?

Modifying 5-HT1A Receptor Gene Expression as a New Target for Antidepressant Therapy

Down-regulation of 5-HT1A autoreceptor expression, not simply desensitization of receptor signaling, appears to be required to enhance and accelerate antidepressant action.

Improving the treatment of schizophrenia: focus on serotonin (5-HT)(1A) receptors.

  • M. Millan
  • Psychology, Biology
    The Journal of pharmacology and experimental therapeutics
  • 2000
Clinical studies of antipsychotics interacting with 5-HT(1A) receptors are required to establish their genuine pertinence to the-hopefully improved-treatment of schizophrenia.

Serotonin 5-HT1a Receptor Agonists as Antidepressants

For 20 years serotonin 5-HT1A receptor agonists have been evaluated for effectiveness in treating depressive disorders and depressive symptoms occurring in a range of diagnostic categories, including major and minor depression, mixed states of anxiety and depression, and mixed syndromes of depression and alcohol dependence.

Serotonin 5-HT1A receptor binding in people with panic disorder: positron emission tomography study.

  • J. NashP. Sargent D. Nutt
  • Medicine, Biology
    The British journal of psychiatry : the journal of mental science
  • 2008
Panic disorder is associated with reduced 5-HT(1A) receptor availability, which is also known to have a key role in depression.
...